Amicus Therapeutics Inc (NASDAQ: FOLD) is -20.58% lower on its value in year-to-date trading and has touched a low of $9.70 and a high of $14.57 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FOLD stock was last observed hovering at around $11.75 in the last trading session, with the day’s loss setting it -0.48%.
Currently trading at $11.27, the stock is -3.22% and -10.00% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.45 million and changing -4.09% at the moment leaves the stock -8.50% off its SMA200. FOLD registered 1.71% gain for a year compared to 6-month gain of 3.78%. The firm has a 50-day simple moving average (SMA 50) of $8.73 and a 200-day simple moving average (SMA200) of -$37.85.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.09% loss in the last 1 month and extending the period to 3 months gives it a -17.44%, and is -0.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.06% over the week and 3.22% over the month.
Amicus Therapeutics Inc (FOLD) has around 517 employees, a market worth around $3.33B and $399.36M in sales. Fwd P/E is 28.42. Profit margin for the company is -37.96%. Distance from 52-week low is 16.19% and -22.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-25.39%).
Amicus Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.06 with sales reaching $111.96M over the same period.The EPS is expected to grow by 100.97% this year, but quarterly earnings will post 33.00% year-over-year. Quarterly sales are estimated to grow 34.80% in year-over-year returns.
320 institutions hold shares in Amicus Therapeutics Inc (FOLD), with institutional investors hold 110.41% of the company’s shares. The shares outstanding are 293.59M, and float is at 286.56M with Short Float at 11.34%. Institutions hold 109.58% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 28.49 million shares valued at $321.11 million. The investor’s holdings represent 9.65% of the FOLD Shares outstanding. As of Dec 30, 2023, the second largest holder is Perceptive Advisors Llc with 28.06 million shares valued at $316.21 million to account for 9.50% of the shares outstanding. The other top investors are Avoro Capital Advisors LLC which holds 27.4 million shares representing 9.28% and valued at over $308.8 million, while Blackrock Inc. holds 7.78% of the shares totaling 22.99 million with a market value of $259.08 million.
Amicus Therapeutics Inc (FOLD) Insider Activity
The most recent transaction is an insider sale by Campbell Bradley L, the company’s President and CEO. SEC filings show that Campbell Bradley L sold 7,500 shares of the company’s common stock on Apr 01 ’24 at a price of $11.67 per share for a total of $87496.0. Following the sale, the insider now owns 0.89 million shares.
Amicus Therapeutics Inc disclosed in a document filed with the SEC on Mar 05 ’24 that MCGLYNN MARGARET G (Director) sold a total of 7,500 shares of the company’s common stock. The trade occurred on Mar 05 ’24 and was made at $13.40 per share for $0.1 million. Following the transaction, the insider now directly holds 59289.0 shares of the FOLD stock.
Still, SEC filings show that on Mar 04 ’24, MCGLYNN MARGARET G (Director) disposed off 7,500 shares at an average price of $13.29 for $99675.0. The insider now directly holds 59,289 shares of Amicus Therapeutics Inc (FOLD).
